Company intelligence / Profile preview

Anodyne Devices

Boston, Massachusetts, United Statestheheropatch.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Anodyne Nanotech has demonstrated preclinical efficacy of its APJ receptor agonist delivered via HeroPatch in improving muscle strength equivalent to daily injections. The company’s lead asset is a once-weekly transdermal GLP‑1 patch for obesity, with plans to enter clinical trials in 2026. Their technology enables co-formulation of multiple agents, potentially addressing both obesity and sarcopenia simultaneously. No human clinical results have been published yet.

Therapeutic areas: Metabolic DisordersOncologyEndocrinologyImmunology
Modalities: DeviceBiologicPeptidesSmall molecule
Industry: Biotech

Partnerships

Early collaborations with leading pharmaceutical partners are referenced but no specific names disclosed.Open to strategic partnerships and co-development opportunities.

Beyond the preview

Go deeper on Anodyne Devices.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anodyne Devices.